Form 4: Intellia Therapeutics Director Muna Bhanji Granted New Equity Awards

Intellia Therapeutics, Inc. Director Muna Bhanji was granted 8,000 restricted stock units and options to purchase 11,450 shares of common stock, as disclosed in a recent SEC Form 4 filing.

Summary

• Muna Bhanji, a Director of Intellia Therapeutics, Inc. (NTLA), reported changes in beneficial ownership of the company's securities.
• On June 11, 2025, Ms. Bhanji was granted 8,000 shares of Common Stock in the form of restricted stock units (RSUs) at a price of $0.00 per unit.
• Following this transaction, Ms. Bhanji beneficially owns 27,203 shares of Common Stock directly.
• Additionally, on June 11, 2025, Ms. Bhanji was granted stock options to purchase 11,450 shares of Common Stock with an exercise price of $8.37 per share.
• These stock options vest in full on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders following the grant date, and expire on June 10, 2035.
• After this transaction, Ms. Bhanji beneficially owns 11,450 derivative securities (stock options) directly.
• The filing was signed by Edward Dulac, attorney-in-fact for Muna Bhanji, on June 13, 2025, under a Limited Power of Attorney dated October 31, 2024.

Sentiment

Score: 7

Explanation: The sentiment is positive as a director is acquiring additional equity in the company through compensation grants, which generally signals confidence in the company's future and aligns insider interests with shareholders.

Positives

• The grant of restricted stock units and stock options to a director aligns the director's interests with those of the shareholders, as their compensation is tied to the company's future performance.
• The acquisition of additional equity by an insider can be viewed as a sign of confidence in the company's future prospects.

Risks

• The Power of Attorney document includes an indemnification clause where the undersigned (Muna Bhanji) agrees to indemnify the attorney-in-fact and the Company against any demand, damage, loss, cost, or expense arising from false or misleading information provided by the undersigned to the attorney-in-fact, highlighting the importance of accurate disclosure.

Future Outlook

The granted stock options are subject to a vesting schedule, which will occur on the earlier of the first anniversary of the grant date (June 11, 2026) or the date of the next annual meeting of stockholders following the grant date. The options have a long-term expiration date of June 10, 2035.

Industry Context

This Form 4 filing is a routine disclosure of insider equity compensation within the biotechnology industry. It reflects standard practices for aligning director incentives with company performance, common across publicly traded companies, particularly in sectors like biotech where long-term development cycles are prevalent.

Corporate Governance

Related Party Transactions

• The grants of restricted stock units and stock options to Director Muna Bhanji represent compensation arrangements between the company and a related party (a director), which are standard practices for executive and director remuneration.

Stakeholder Impact

• Shareholders: The equity grants align the director's financial interests with shareholder value creation, potentially leading to more focused decision-making aimed at increasing stock price.
• Employees: While not directly impacted, the compensation structure for directors can reflect broader company policies on equity incentives.

Next Steps

• The granted stock options will vest on the earlier of June 11, 2026 (first anniversary of grant) or the date of the next annual meeting of stockholders following the grant date.

Key Dates

Keywords

Intellia Therapeutics, NTLA, SEC Form 4, Insider Trading, Restricted Stock Units, Stock Options, Equity Compensation, Director Compensation, Beneficial Ownership, Biotechnology, Gene Editing